Tumor necrosis factor receptor-associated factor 4 (TRAF4)

Tumor necrosis factor receptor-associated factor 4 (TRAF4) is an E3 ubiquitin ligase and unique member of the TRAF protein family involved in transducing signals from various cell surface receptors, primarily regulating cell survival, death, migration, and immune responses[1][2][3]. Unlike other TRAFs, TRAF4 shows nuclear localization and has a distinctive structure, including domains for protein-protein interactions (RING finger, TRAF domain, zinc fingers)[2][5][6]. It participates in multiple signaling pathways relevant to development and disease, notably playing regulatory roles in cancer progression, inflammation, and neurobiology. TRAF4 is overexpressed in many cancers (notably breast cancer), where it promotes cell proliferation, survival, migration, and invasion via stabilizing tight junctions, activating AKT and ERK, and modulating Wnt/β-catenin and TGF-β/SMAD pathways[1]. While it interacts with numerous signaling partners, no approved small molecule inhibitors or drugs directly target human TRAF4. Its function as a signaling hub and E3 ligase, together with its disease associations, make TRAF4 a candidate therapeutic and biomarker target, though targeting is complicated by its broad and essential physiological roles.

Other names

RING finger protein 83RNF83Metastatic lymph node gene 62 proteinMLN62CART1Cysteine-rich domain associated with RING and Traf domains protein 1Malignant 62TRAF-4

Modulation of signaling pathways including MAPK/ERK, PI3K/AKT, JNK, Wnt/β-catenin, TGF-β/SMAD, NF-κB; E3 ubiquitin ligase activity affecting substrate ubiquitination; Scaffold facilitating assembly of signaling complexes